AVX701
AXP000213.1 · Cancer vaccine
- Platform
- alphavirus (VEE) virus-like replicon particles
- Targets
- CEACAM5
- Originator
- AlphaVax
- Sponsor
- AlphaVax / Duke University
Names
Virus
- Role
- Vaccine vector
- Family
- Togaviridae
- Virus
- Venezuelan equine encephalitis virus (NCBI Taxonomy 11036)
- Strain
- VEE replicon, packaged as virus-like replicon particles
- Replication
- non replicating
- Modifications
- structural protein genes replaced by the transgene so the replicon cannot be amplified further in the recipient; particles packaged with structural proteins supplied in trans
- Transgenes
- CEACAM5 (CEA(6D))
- Route
- intramuscular
- Source
- evidence
Cross-references
- NCI Thesaurus
- C70644
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT01890213 | Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer | Completed | Phase 1 | 2013-11 | 2017-06 | 12 | Stage III Colon Cancer |
| NCT00529984 | A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies | Completed | Phase 1/2 | 2007-09 | 2010-05 | 28 | Breast Cancer; Colon Cancer; Colorectal Cancer; Lung Cancer; Pancreatic Cancer |
Recent changes
No changes recorded in its trials yet.
Notes
Propagation-defective Venezuelan equine encephalitis virus replicon packaged as virus-like replicon particles encoding CEA(6D); intramuscular. Phase 1/2 in advanced CEA-expressing cancer (NCT00529984, PMID 20679728). Included as a cancer vaccine, which this pass admits at any phase.
How to cite
AVX701 (AXP000213.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000213.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.